Updated: Oct 8, 2021
If school-aged children were at significant health risk from COVID-19 infection, or if immunity resulting from natural infection were not effective, then the cost to benefit conclusions would be different. However, for young people 18 and under, successful recovery rates are extremely high, rates of long-term COVID-19 symptoms are low, and natural immunity is proving strong. Therefore, the risks of side effects from the vaccination likely outweigh the benefits for a majority of students. And, per the latest studies, for students carrying antibodies from previous COVID-19 infection, the known side effects and long-term risks from vaccination most assuredly outweigh the risks of contracting COVID-19.
 https://www.npr.org/sections/coronavirus-live-updates/2021/08/10/1026375608/nearly-94-000-kids-got-covid-19-last-week-they-were-15-of-all-new-infections  https://www.scmp.com/news/world/middle-east/article/3146656/past-covid-19-reduces-risk-reinfection-delta-variant-pfizer  https://www.statista.com/statistics/1191568/reported-deaths-from-covid-by-age-us/  https://www.statista.com/statistics/1254271/us-total-number-of-covid-cases-by-age-group/  https://www.medpagetoday.com/opinion/marty-makary/93029